Mustang Bio

Mustang Bio, a Fortress Biotech company, is focused on the development of novel immunotherapies and gene therapies in areas of unmet need.

[Mustang Bio @Mustang_Bio]

On Rare Disease Day, we are proud to be a part of the global rare disease community and remain driven by one goal: progress for patients. #RareDiseaseDay #Glioblastoma #MustangBio

[Mustang Bio @Mustang_Bio]

Rare Disease Day highlights a global challenge: 300+ million people are affected by rare diseases, many with limited or no treatment options.

[Mustang Bio @Mustang_Bio]

At Mustang Bio, we’re advancing innovative therapies for devastating conditions, including glioblastoma, an aggressive and rare brain cancer with significant unmet need.

[Mustang Bio @Mustang_Bio]

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma $MBIO $FBIO https://t.co/gCJr3AoT5J

[Mustang Bio @Mustang_Bio]

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy $MBIO $FBIO https://t.co/gMMZkCHIg7

[Mustang Bio @Mustang_Bio]

Mustang Bio announces expansion into #autoimmunediseases with MB-106, a CD20-targeted autologous CAR T-cell therapy. A Phase 1 trial is expected to initiate in the 4th quarter of this year to demonstrate clinical proof-of-concept. $MBIO Learn more: https://t.co/rWFtJLzgPy

[Mustang Bio @Mustang_Bio]

Mustang Bio reports full-year 2023 financial results and recent corporate highlights. $MBIO Read more here: https://t.co/GoA9tfNZCl

[Mustang Bio @Mustang_Bio]

https://t.co/Z9nt0u5iGJ

[Mustang Bio @Mustang_Bio]

Phase 1 data published in @NatureMedicine demonstrate the promising safety and clinical activity of Mustang’s MB-101 IL13Ra2-targeted CAR T-cells for the treatment of patients with recurrent and refractory malignant glioma, including #glioblastoma. $MBIO

[Mustang Bio @Mustang_Bio]

#DYK one out every 10 Americans is living with a rare disease? This #RareDiseaseDay, learn more about Mustang's pipeline and its treatments for rare diseases. https://t.co/XKrqNuAS6J #XSCID #BubbleBoyDisease #WaldenstromMacroglobulinemia #GBM $MBIO

[Mustang Bio @Mustang_Bio]

This #RareDiseaseDay, learn more about #WM and Mustang Bio’s ongoing MB-106 Phase 1/2 trial here: https://t.co/rZwHvrJNOY #CD20-targetedCAR T-cell #WaldenstromMacroglobulinemia $MBIO

[Mustang Bio @Mustang_Bio]

#DYK Waldenstrom Macroglobulinemia (WM) is a rare #bloodcancer that originates from malignant B-cells and there is no FDA-approved therapy or standard of care in the third-line setting? There are about 1,400 new patients per year in the U.S. who are diagnosed with the disease.

[Mustang Bio @Mustang_Bio]

This #RareDiseaseDay, learn more Mustang Bio’s MB-117 and MB-217 gene therapies to treat XSCID here: https://t.co/rZwHvrJNOY #XSCID #BubbleBoyDisease $MBIO

[Mustang Bio @Mustang_Bio]

#DYK X-Linked Severe Combined Immunodeficiency (XSCID), also commonly known as #BubbleBoyDisease, is a rare mutation in the interleukin 2 receptor gamma (IL2RG) gene that makes a newborn immunocompromised?

[Mustang Bio @Mustang_Bio]

There are about 30-40 new patients per year in the U.S. who are diagnosed with the disease and without treatment, most patients do not live past the age of one.

[Mustang Bio @Mustang_Bio]

This #RareDiseaseDay, learn more here: https://t.co/rZwHvrKlEw #glioblastoma #GBM #braincancer #CAR-T $MBIO

[Mustang Bio @Mustang_Bio]

#DYK recurrent glioblastoma (GBM) is a rare and aggressive #braincancer that impacts approximately 12,000 patients in the US annually? Mustang is developing MB-109, a CAR-T cell therapy and oncolytic virus combination, to potentially treat recurrent GBM more effectively.

[Mustang Bio @Mustang_Bio]

Learn more about the rare diseases that Mustang Bio is developing treatments for at https://t.co/1Fq2207NVS and check out the NORD site to see how you can #ShowYourStripes in support of the 300 million people with rare diseases and disabilities worldwide.

[Mustang Bio @Mustang_Bio]

Get ready for #RareDiseaseDay on February 29. One out of every 10 Americans is living with a rare disease. $MBIO https://t.co/P5jJgklVBa

[Mustang Bio @Mustang_Bio]

Reminder: Mustang Bio’s Robert Sexton, VP, Program & Alliance Leadership, will speak at the Reuters Events Pharma exclusive webinar this morning at 10a.m. ET. $MBIO $FBIO For more details: https://t.co/Stwn24nqSJ